UHealth is not currently offering monoclonal antibody therapy for treatment of COVID-19 except in rare cases where strict criteria are met. Omicron is the dominant variant strain in South Florida and data has shown that bamlanivimab/etesevimab (by Eli Lilly) and casirivimab/imdevimab (by Regeneron) are not effective against this variant.